Month: March 2023

Demonstrates Strong 2022 Results and Continued Momentum Into 2023, Backed by Record Annual Sales Bookings and Order Fulfillment Performance Full Year 2023 Guidance of Annual Service Fee Revenue Growth of 5% to 10% IRVING, Texas, March 14, 2023 (GLOBE NEWSWIRE) — PFSweb, Inc. (NASDAQ: PFSW) (the “Company”) is reporting results for the fourth quarter and full year ended December 31, 2022. “2022 was a strong year for PFS as we leveraged ongoing tailwinds in the eCommerce industry,” said Mike Willoughby, CEO of PFSweb. “Across our core verticals, our client brands focusing on premium and luxury goods proved resilient by delivering strong holiday order volumes. These tailwinds and our customized, brand centric operational capabilities helped deliver our previously announced record sales bookings year in 2022, generating...

Enrollment in the company’s Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023. The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States. The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and neck cancer, or bladder cancer. The company anticipates reporting additional data from this study over the course of 2023. The company ended 2022 with...

– Issues Full Year 2023 Guidance – GREAT NECK, N.Y., March 14, 2023 (GLOBE NEWSWIRE) — BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust that owns, operates, and, to a lesser extent, holds interests in joint ventures that own multi-family properties, today reported results for the fourth quarter and year ended December 31, 2022, and issued guidance for expected full year 2023 results. HighlightsReported results for the fourth quarter of 2022 of a net loss of $4.2 million, or $(0.22) per diluted share, Funds from Operations, or FFO, of $0.40 per diluted share and Adjusted Funds from Operations, or AFFO, of $0.37 per diluted share. Reported results for 2022 of net income of $50.0 million, or $2.66 per diluted share, FFO of $1.24 per diluted share and AFFO of $1.52 per diluted share. Equity in earnings of unconsolidated...

Key 4Q22 metrics exceeded guidance on strength of 2022 execution; Revenue of R$2.7 billion, + 44% y/y (vs R$2.6+ billion guidance); Adj. EBT of R$316 million, +50% q/q (vs R$250+ million guidance); MSMB TPV of R$81.9 billion, +23% year over year (vs R$78.0 – R$79.0 billion guidance) GEORGE TOWN, Grand Cayman, March 14, 2023 (GLOBE NEWSWIRE) — StoneCo Ltd. (Nasdaq: STNE) (“Stone” or the “Company”) today reports its financial results for its fourth quarter and fiscal year ended December 31, 2022. “Dear Shareholders, This quarter, I would like to highlight our evolution along 2022. As I transition to the board role and hand the executive leadership to Pedro, I also want to reflect back on what I think makes your company great and what I believe will be the foundation for its success over the next decades. I think 2022 was a...

Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Ongoing with Data Expected Mid-Year   Continued Progress Across Pipeline of GeneTAC™ Small Molecules with Three Programs Expected to be in Clinical Development in the Next Two Years Strong Financial Position with $330 Million in Cash and Securities Expected to Support Operating Runway through 2025 CARLSBAD, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today highlighted recent progress and anticipated upcoming milestones across its clinical and research-stage pipeline of novel GeneTAC™ small molecules and reported fourth quarter and full year 2022 financial results. “We are very proud of the important progress...

Net Sales for the Fourth Quarter and Full Year 2022 Increase by 20% and 24%, Respectively Net Loss of $55.5 Million and Adjusted EBITDA of $60.1 Million for the Full Year 2022, Representing Adjusted EBITDA Growth of 27% Strategic Acquisition of West Coast-Based Bixby Coffee Expands Influencer Marketing Sales Channel Adjusted EBITDA Expected to Grow 10% to 25% in Fiscal 2023 LITTLE ROCK, Ark., March 14, 2023 (GLOBE NEWSWIRE) — Westrock Coffee Company (Nasdaq: WEST) (“Westrock Coffee” or “the Company”) today reported financial results for the fourth quarter and full year 2022. Scott T. Ford, CEO and Co-founder, stated, “We are pleased to announce strong growth in net sales, gross profit and Adjusted EBITDA for full year 2022. I am very grateful to the team for their near heroic efforts that delivered record annual results, even...

Jerry Guo to Retire as President and CEO, Remains on Casa Board of DirectorsBruce Evans Appointed New Chairman of Expanded Board of DirectorsScott Bruckner Joins the Board of Directors Q4 Revenue of $84.4 Million Slightly Exceeds High End of Preliminary Guidance GAAP Net Income of $1.2 Million and Positive Net Adjusted EBITDA of $5.2 Million for Quarter Debt Reduced by $49.2 Million to $226.0 Million during Q4 Provides Full Year Revenue and Net Adjusted EBITDA Guidance ANDOVER, Mass., March 14, 2023 (GLOBE NEWSWIRE) — Casa Systems, Inc. (Nasdaq: CASA), a leading provider of cloud-native software and physical broadband technology solutions for wireless, cable, and fixed networks, today announced that the Company’s President and Chief Executive Officer will be retiring, and reported its financial results for the fourth quarter and...

– Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients – – Plan to initiate the CHORD™ trial in the First Half of 2023 – – Presented key non-clinical data at the 46th Annual ARO MidWinter Meeting supporting compelling safety profile of DB-OTO and preclinical data supporting selection of AAV.103 product candidate – BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. “I am...

– Infrastructure: DBM Global finishes year strong; achieves 37% revenue growth for 2022 –– Life Sciences: MediBeacon completed enrollment of both U.S. and China Pivotal Studies –– Spectrum: Broadcasting added contracts with three major networks and launched new programming – – Company meets Continued Listing Standards from NYSE – NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) — INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the fourth quarter and fiscal year ended December 31, 2022. Financial Summary(in millions, except per share amounts) Three Months Ended December 31,   Years Ended December 31,    2022       2021     Increase / (Decrease)     2022       2021     Increase / (Decrease)Revenue $ 409.3     $ 394.8     3.7 %   $ 1,637.3     $ 1,205.2     35.9 %Net...

Record-Breaking Full Year 2022 Net Revenue of $440 million, up 17% from 2021 Full Year Net Income of $3.7 million, up 82% from 2021 Grew Active Customers, up 17% from 2021 CHICO, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Lulu’s Fashion Lounge Holdings, Inc. (“Lulus” or the “Company”) (Nasdaq: LVLU) today reported financial results for the fourth quarter and full year ended January 1, 2023. Crystal Landsem, CEO of Lulus, said: “We’re proud to have completed our first full year as a public company on solid ground with a clean balance sheet free of high-cost term debt, which enabled us to continue investing in the business. We saw year-over-year growth in repeat customers during the fourth quarter, as well as healthy year-over-year growth in Active Customers, which shows that our brand continues to resonate with our customers. Like...